000 02253naaaa2200373uu 4500
001 https://directory.doabooks.org/handle/20.500.12854/77570
005 20220219213820.0
020 _aintechopen.91512
020 _a9781839686245
020 _a9781839686238
020 _a9781839686252
024 7 _a10.5772/intechopen.91512
_cdoi
041 0 _aEnglish
042 _adc
072 7 _aMJJ
_2bicssc
100 1 _aRodrigo, Luis
_4edt
700 1 _aMartins, Ian
_4edt
700 1 _aGuo, Xiaozhong
_4edt
700 1 _aQi, Xingshun
_4edt
700 1 _aRodrigo, Luis
_4oth
700 1 _aMartins, Ian
_4oth
700 1 _aGuo, Xiaozhong
_4oth
700 1 _aQi, Xingshun
_4oth
245 1 0 _aAdvances in Hepatology
260 _bIntechOpen
_c2021
300 _a1 electronic resource (258 p.)
506 0 _aOpen Access
_2star
_fUnrestricted online access
520 _aThis book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.
540 _aCreative Commons
_fhttps://creativecommons.org/licenses/by/3.0/
_2cc
_4https://creativecommons.org/licenses/by/3.0/
546 _aEnglish
650 7 _aHepatology
_2bicssc
856 4 0 _awww.oapen.org
_uhttps://www.intechopen.com/books/10326
_70
_zDOAB: download the publication
856 4 0 _awww.oapen.org
_uhttps://directory.doabooks.org/handle/20.500.12854/77570
_70
_zDOAB: description of the publication
999 _c45415
_d45415